-

Adamas to Present at Upcoming Healthcare Conferences

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, Chief Executive Officer, is scheduled to present at the following investor conferences:

  • 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24 at 1:40 p.m. ET (10:40 a.m. PT)
  • Cowen 41st Annual Healthcare Conference on Tuesday, March 2 at 2:50 p.m. ET (11:50 a.m. PT)
  • H.C. Wainwright Global Life Sciences Conference. Prerecorded presentation available starting on Tuesday, March 9 at 7:30 a.m. ET (4:30 a.m. PT)

The webcasts will be accessible on the investor relations section of the Adamas website at http://ir.adamaspharma.com/events-presentations and will be available for 30 days.

About Adamas Pharmaceuticals, Inc.

At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visit www.adamaspharma.com.

Source: Adamas Pharmaceuticals, Inc.

Contacts

Media:
Sarah Mathieson
Vice President, Corporate Communications
510-450-3528
smathieson@adamaspharma.com

Investors:
Peter Vozzo
Managing Director
Westwicke/ICR
443-213-0505
peter.vozzo@westwicke.com

Adamas Pharmaceuticals, Inc.

NASDAQ:ADMS

Release Versions

Contacts

Media:
Sarah Mathieson
Vice President, Corporate Communications
510-450-3528
smathieson@adamaspharma.com

Investors:
Peter Vozzo
Managing Director
Westwicke/ICR
443-213-0505
peter.vozzo@westwicke.com

More News From Adamas Pharmaceuticals, Inc.

Adamas Announces New Employment Inducement Grants

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted eight new employees restricted stock units to acquire 106,500 shares of the company’s common stock. The restricted stock units vest over three years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of...

Adamas Named 2021 Finalist in the New Therapeutics Category of the UCSF Health Awards

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has been selected as one of five finalists in the UCSF Health Awards 2021 New Therapeutics category. This year’s UCSF Health Awards program, which historically focused on the digital health tech industry, was expanded to include several life science categories...

Adamas Announces GOCOVRI Presentations at the Upcoming International Parkinson and Movement Disorder Society’s (MDS) Congress

EMERYVILLE, Calif.--(BUSINESS WIRE)--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced five posters will be presented at the International Parkinson and Movement Disorder Society (MDS) Virtual Congress, taking place September 17 – 22, 2021. The poster presentations will focus on GOCOVRI® (amantadine) extended-release capsules, the first and only FD...
Back to Newsroom